Sleep apnea statistics show a large and varied health burden: global estimates count hundreds of millions of adults with obstructive sleep apnea (OSA), while prevalence changes substantially with age, diagnostic thresholds, pregnancy and study method. The figures below distinguish modeled estimates, observed studies, trials and retrospective associations.
Key Sleep Apnea Statistics
The most broadly useful figures include:
- In the 2019 global estimate, 936 million adults aged 30–69 had mild-to-severe OSA at an apnea-hypopnea index (AHI) of at least 5 events per hour.
- In the 2019 global estimate, 425 million adults aged 30–69 had moderate-to-severe OSA at an AHI of at least 15 events per hour.
- The 2019 global model placed the 95% interval for mild-to-severe OSA at 903–970 million adults worldwide.
- The 2019 global model placed the 95% interval for moderate-to-severe OSA at 399–450 million adults worldwide.
- In 2024, 83.7 million U.S. adults aged 20 or older were estimated to have OSA.
- The estimated 2024 U.S. adult OSA prevalence was 32.4%.
- The 2024 U.S. estimate included 49,459,041 males and 34,257,378 females with OSA.
- A review of studies through 2016 found general adult OSA prevalence of 9%–38% at AHI ≥5.
- The same review found general adult OSA prevalence of 6%–17% at AHI ≥15.
- A meta-analysis of 33 studies through January 2018 estimated 15% OSA prevalence among pregnant women worldwide.
- Preschool OSA estimates from studies published in 2016–2023 ranged from 12.8% to 20.4% after outliers were excluded.
- A 2022 meta-analysis found 2.36-times higher car-accident odds among adults with OSAS than controls.
- In a U.S. cohort diagnosed from June 2014 through April 2018, adherent PAP users averaged 0.39 ER visits in year 1, versus 0.54 among non-adherent users.
- In that cohort, year-1 total estimated costs averaged $5,874 per adherent PAP user, versus $6,355 per non-adherent user.
- Across the JAMA trials reviewed, PAP adherence ranged from 1.4 to 6.6 hours per day.
- A 2024 mortality review found observational PAP use associated with all-cause mortality HR 0.60 after excluding the largest study.
- In randomized trials in that 2024 review, all-cause mortality HRs were 0.95 at 2 hours, 0.84 at 4 hours and 0.74 at 6 hours of nightly PAP use.
Contents
- How common sleep apnea is worldwide and in the United States
- How sleep apnea prevalence varies by age, sex, body size and pregnancy
- Sleep apnea severity, testing thresholds and detection
- Sleep apnea in children, pregnancy and road safety
- Sleep apnea health-care use and economic costs
- PAP treatment adherence and measured outcomes
How common sleep apnea is worldwide and in the United States
The global figures come from a 2019 literature-based analysis of adults aged 30–69. Its standardized estimates are useful for scale, but they are a model rather than a worldwide diagnostic census.
| Population and threshold | Estimate | Period and scope |
|---|---|---|
| Global adults aged 30–69, mild-to-severe OSA, AHI ≥5 | 936 million | 2019 estimate |
| Global adults aged 30–69, moderate-to-severe OSA, AHI ≥15 | 425 million | 2019 estimate |
| 95% interval, mild-to-severe OSA | 903–970 million | 2019 estimate |
| 95% interval, moderate-to-severe OSA | 399–450 million | 2019 estimate |
The analysis had reliable prevalence data from 16 countries and 17 studies; other countries were modeled. China, the United States, Brazil and India ranked first through fourth for estimated OSA counts in the global analysis.
For the United States, a 2024 projection estimated OSA in 83.7 million adults aged 20 or older, equivalent to 32.4% of that population. The projection used literature and obesity fractions, so it should not be read as a direct diagnostic survey.
| U.S. adult group | Estimated people with OSA | Measurement period |
|---|---|---|
| Males aged 20 or older | 49,459,041 | 2024 projection |
| Females aged 20 or older | 34,257,378 | 2024 projection |
Source: Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States.
How sleep apnea prevalence varies by age, sex, body size and pregnancy
Prevalence is not a single fixed percentage. A systematic review of general-population studies through 2016 found broad ranges because populations, scoring rules and testing methods differed.
- General adult OSA prevalence ranged from 9% to 38% at AHI ≥5.
- General adult OSA prevalence ranged from 6% to 17% at AHI ≥15.
- In some elderly groups, OSA at AHI ≥5 reached 90% in men and 78% in women.
- In advanced-age groups, OSA at AHI ≥15 was reported as high as 49%.
These upper-end subgroup results are not estimates for every older adult. They illustrate why age composition and the selected AHI threshold materially affect comparisons.
Source: Prevalence of obstructive sleep apnea in the general population: A systematic review.
Pregnancy has its own evidence base. A 33-study meta-analysis through January 2018 estimated pooled OSA prevalence at 15% worldwide, with regional estimates from 5% in Europe to 20% in the Americas.
Across trimesters, synthesized estimates ranged from 15% to 19%. The review noted that objective methods varied, so these figures should be compared cautiously.
Sleep apnea severity, testing thresholds and detection
The AHI counts breathing interruptions or reductions per hour of sleep, but the exact definition used in a study matters. The 2024 U.S. estimate used AHI4 of at least 5 events per hour, with hypopneas linked to at least 4% oxygen desaturation.
| Category in the 2024 U.S. estimate | AHI4 range |
|---|---|
| Mild OSA | 5 to under 15 events/hour |
| Moderate OSA | 15 to under 30 events/hour |
| Severe OSA | ≥30 events/hour |
The global analysis standardized OSA using AASM 2012 AHI thresholds of ≥5 and ≥15 events per hour. Its scoring conversion and the U.S. estimate’s AHI4 oxygen rule mean that apparently similar prevalence figures may not represent identical case definitions.
Source: Unmasking obstructive sleep apnea: Estimated prevalence and impact in the United States; Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.
Detection is especially limited in preschool research. Across studies through 2023, only 82 of 4,575 preschool children, or 1.2%, received polysomnography after screening.
Two objective-threshold definitions produced estimates of 1.8% and 6.4%, while questionnaire-heavy studies produced much wider ranges.
Sleep apnea in children, pregnancy and road safety
Preschool estimates changed across publication periods, but the change cannot be interpreted as a definite biological trend because methods may explain part of the difference.
| Preschool study period | Reported OSA prevalence | Important scope note |
|---|---|---|
| Before 2014 | 3.3%–9.4% | Most used questionnaires |
| 2016–2023 | 12.8%–20.4% | Outliers excluded; methods may explain change |
In pregnancy, the meta-analysis reported associations—not proof that OSA caused the outcomes. Adjusted odds ratios were 1.97 for gestational hypertension, 1.55 for gestational diabetes, 2.35 for pre-eclampsia and 1.62 for preterm birth.
Road-safety evidence also concerns association. A 30-study meta-analysis published in 2022, covering studies through May 3, 2021, found car-accident odds 2.36 times higher among adults with OSAS than controls.
| Driver group | Car-accident odds ratio | Study scope |
|---|---|---|
| Commercial drivers | 2.80 | Heterogeneous subgroup |
| Noncommercial drivers | 2.32 | Heterogeneous subgroup |
Sources: The prevalence of obstructive sleep apnea and its association with pregnancy-related health outcomes: a systematic review and meta-analysis; Correlations of Obstructive Sleep Apnea Syndrome and Daytime Sleepiness with the Risk of Car Accidents in Adult Working Population: A Systematic Review and Meta-Analysis with a Gender-Based Approach; Prevalence of obstructive sleep apnea (OSA) among preschool aged children in the general population: A systematic review.
Sleep apnea health-care use and economic costs
A retrospective U.S. study followed newly diagnosed adults with OSA diagnosed from June 2014 through April 2018. In its first year after PAP, adherent users averaged 0.39 ER visits per person compared with 0.54 among non-adherent users, and 0.09 hospitalizations compared with 0.13.
| Year 1 outcome per person | Adherent PAP | Non-adherent PAP |
|---|---|---|
| ER visits | 0.39 | 0.54 |
| Hospitalizations | 0.09 | 0.13 |
| Total estimated costs | $5,874 | $6,355 |
| Inpatient costs | $990 | $1,601 |
| ER costs | $306 | $409 |
The study reported a 28% lower ER-visit rate for adherent users, with rate ratio 0.72, and a 31% lower hospitalization rate, with rate ratio 0.69. In year 2, ER visits averaged 0.38 per adherent person versus 0.52 among non-adherent users, while total estimated costs averaged $4,895 versus $5,135.
These are proxy cost estimates and retrospective associations, not proof that adherence alone caused the differences.
Source: Healthcare Resource Utilization and Costs in Treated Obstructive Sleep Apnea Patients.
PAP treatment adherence and measured outcomes
Positive airway pressure (PAP) studies use different designs and follow-up periods. Across trials reviewed in JAMA, adherence ranged from 1.4 to 6.6 hours per day, and follow-up ranged from 6 to 68 months.
The JAMA review reported 356 major adverse cardiovascular events and 613 deaths across included trials. The review included OSA and central apnea, and the aggregated results span different trial designs.
The 2024 mortality meta-analysis found an observational association between PAP and lower all-cause mortality: hazard ratio 0.60, with a 95% confidence interval of 0.51–0.71, after excluding the largest study. Confounding remains possible in non-randomized evidence.
In randomized trials, reported all-cause mortality hazard ratios by nightly PAP use were 0.95 at 2 hours, 0.84 at 4 hours and 0.74 at 6 hours. The review cautioned that this was not a significant causal dose response.
Pooled cardiovascular-mortality risk was lower with PAP than without PAP, with HR 0.45 and a 95% confidence interval of 0.29–0.72, but the pooled estimate combined randomized and non-randomized studies.
In the linked U.S. cohort, 65,983 patients were adherent, 72,711 intermediate-adherent and 40,848 non-adherent across eight 90-day quarters. The CMS-style adherence criterion required at least 4 hours per night on at least 70% of nights in a 30-day period; this is a compliance definition, not a universal measure of effectiveness.
Sources: Association of Positive Airway Pressure With Cardiovascular Events and Death in Adults With Sleep Apnea: A Systematic Review and Meta-analysis; Positive airway pressure therapy and all-cause and cardiovascular mortality in people with obstructive sleep apnoea: a systematic review and meta-analysis of randomised controlled trials and confounder-adjusted, non-randomised controlled studies; Healthcare Resource Utilization and Costs in Treated Obstructive Sleep Apnea Patients.
These statistics are descriptive medical evidence, not personal advice. Prevalence differs by population, AHI threshold, oxygen rule, questionnaire and objective test, while cost and PAP outcome estimates may be modeled or retrospective rather than causal.